Bressler, S., D. Liu, A. Glassman, B. Blodi, A. Castellarin, L. Jampol, P. Kaufman, M. Melia, H. Singh, and J. Wells. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol., 2017, p. Epub PubMed Text.
Abstract
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents.